L-Arginine/NO Pathway Is Altered in Children with Haemolytic-Uraemic Syndrome (HUS)

Table 1

Clinical characteristics of the haemolytic uraemic syndrome (HUS) patients on the 1st or 2nd day of admission and duration of peritoneal dialysis.

Patient number	Duration of peritoneal dialysis (days)	Neurological events	Hypertension	Serum creatinine (µM)	Serum urea (mM)	Urine albumin (g/L)	Total hemoglobin (g/dL)	Free hemoglobin (mg/L)	Lactate dehydrogenase (U/L)
1	0	No	No	108	15.4	3.7	6.6	429	2448
2	7	No	No	394	28.4	0.37	7.6	196	968
3	30	Ataxy	Yes	256	35.0	0.05	6.8	127	3789
4	5	No	No	458	41.9	0.41	5.9	165	2606
5	9	EEG alteration	No	132	20.4	Not measured	6.8	155	1462
6	24	No	Yes	209	21.0	0.89	5.7	Not measured	2611
7	30	Status epilepticus	No	304	26.3	0.24	4.8	Not measured	2593
8	10	No	No	50	7.8	4.45	6.9	84	3090
9	8	EEG alteration	No	528	39.4	Not measured	13.0	Not measured	2003
10	6	No	No	600	68.0	Not measured	8.2	Not measured	Not measured
11	20	No	Yes	373	19.8	3.4	6.0	Not measured	2662
12	14	EEG alteration	No	296	28.4	4.97	6.2	284	2379